The serum biomarker of Splenic Asthenia and Phlegm-Damp syndrome of NSCLC

  • Ying Tang The First Affiliated Hospital of Guangzhou University of Chinese Medicine
  • Xiong-Wen Wang
  • Zhan-Hua Liu
  • Dai-Han Zhou

Abstract

OBJECTIVE: To identify serum biomarker that could help to diagnose and treat splenic asthenia and phlegm-damp syndrome (SAPDS) of non-small-cell lung cancer (NSCLC).


METHODS: Two-dimensional fluorescence difference gel electrophoresis (2D-DIGE) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) were utilized to analyze proteins expression in serum samples from SAPDS of NSCLC and other syndromes.


RESULTS: MALDI–TOF–MS analysis and database matching identified six spots as the candidate proteins. In addition, we use FunRich software to provide functional enrichment and network analysis integrated with biological process, biological pathway and molecular function of the candidate proteins in SAPDS of NSCLC.


CONCLUSION: The molecular functions of candidate proteins suggest that SAPDS of NSCLC is involved in the activity of complement, protease inhibitor, transcription factor and structural constituent of ribosome. Biological process analysis shows the different between different syndromes of NSCLC in regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism, protein metabolism and immune response. The SAPDS of NSCLC also plays an important role in the biological pathway of the complement cascade; terminal pathway of complement; innate immune system; initial triggering of complement; FOXA1 transcription factor network and immune system.

Published
2017-10-08
How to Cite
TANG, Ying et al. The serum biomarker of Splenic Asthenia and Phlegm-Damp syndrome of NSCLC. Current Science, [S.l.], v. 113, n. Issue 6, oct. 2017. ISSN 0011-3891. Available at: <http://currentscience.org/index.php/CS/article/view/89>. Date accessed: 15 dec. 2017.